Digitisation | April 19, 2024
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Around 7% of the Indian population suffers from IBS
Around 7% of the Indian population suffers from IBS
FDA has concluded that this inspection is 'closed'
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Global Phase-3 study initiation expected in the second half of 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
A significant proportion of healthcare professionals still tend to favor branded drugs
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated
